936092-53-4

Basic information

• Product Name: N-tert-butyl-3-(2-chloro-5-methylpyrimidin-4-ylamino)benzenesulfonamide
• Synonyms: N-tert-butyl-3-(2-chloro-5-methylpyrimidin-4-ylamino)benzenesulfonamide;3-[(2-Chloro-5-methyl-4-pyrimidinyl)amino]-N-(tert-butyl)benzenesulfonamide;BenzenesulfonaMide, 3-[(2-chloro-5-Methyl-4-pyriMidinyl)aMino]-N-(1,1-diMethylethyl)-
• CAS NO: 936092-53-4
• Molecular Formula: C₁₅H₁₉ClN₄O₂S
• Molecular Weight: 354.86
• EINECS: 200-258-5
• Mol File: 936092-53-4.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Density: 1.312
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: N-tert-butyl-3-(2-chloro-5-methylpyrimidin-4-ylamino)benzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-tert-butyl-3-(2-chloro-5-methylpyrimidin-4-ylamino)benzenesulfonamide(936092-53-4)
• EPA Substance Registry System: N-tert-butyl-3-(2-chloro-5-methylpyrimidin-4-ylamino)benzenesulfonamide(936092-53-4)

Safety Data

• Hazardous Substances Data: 936092-53-4(Hazardous Substances Data)

Usage

General Description

N-tert-butyl-3-(2-chloro-5-methylpyrimidin-4-ylamino)benzenesulfonamide is a chemical compound with the molecular formula C16H20ClN5O2S. It is a sulfonamide derivative with a substituted pyrimidine ring and a tert-butyl group. N-tert-butyl-3-(2-chloro-5-methylpyrimidin-4-ylamino)benzenesulfonamide has potential uses in medicinal and chemical research, as it may exhibit biological activity and be used as a building block for the synthesis of other compounds. Its specific properties and potential applications would need to be further studied and evaluated.

Upstream product

• 308283-47-8 3-bromo-(N-tert-butyl)benzenesulfonamide 
• 14394-70-8 2-chloro-4-amino-5-methylpyrimidine 
• 1780-31-0 2,6-dichloro-5-methylpyrimidine 
• 608523-94-0 3-amino-N-(dimethylethyl)benzenesulfonamide 
• 121-51-7 3-nitrobenzenesulphonyl chloride 

Downstream Products

• 936091-15-5 TG₄₆ 
• 936091-26-8 N-tert-butyl-3-{5-methyl-2-[4-(2-pyrrolidin-1-yl-ethoxy)-phenylamino]-pyrimidin-4-ylamino}-benzenesulfonamide 

Relevant articles and documents

Synthesis and biological evaluation of novel 2,4-dianilinopyrimidine derivatives as potent dual janus kinase 2 and histone deacetylases inhibitors

Dual or multiple-targeting inhibition of oncogenic targets in a single molecule could be an alternative approach to drug combinations. Previous studies have revealed that histone deacetylases (HDAC) inhibitor in combination with janus kinase (JAK) inhibitor could exhibit synergistically anti-proliferative effects in cancer treatment. Herein, we presented a novel series of 2,4-dianilinopyrimidine derivatives, which could simultaneously inhibit JAK2 and HDAC1. Among which, 7l was found to be the most potent compound and displayed balanced inhibitory activity against HDAC1 (IC50 = 1.9 nM) and JAK2 (IC50 = 0.5 nM), respectively. 7l also demonstrated good antiproliferative activity against tested cancer cell lines (A549, HepG-2, MDA-MB-231 and Jurkat). Moreover, flow cytometric analysis showed that 7l induced apoptosis and cell cycle arrest in a dose-dependent manner, and the insight into mechanisms of 7l indicated that it could decrease the phosphorylation of STAT-3 and promote histone acetylation. In conclusion, these results together suggested that 7l would be a promising lead candidate and deserved further research and development.

One class HDAC and JAK dual targeting inhibitors. Preparation method and application

HDAC And JAK dual-targeted inhibitors have the structure shown HDAC, and JAK and I dual-targeting inhibitors have good inhibitory activity on HDAC HDAC and JAK JAK kinases. The invention also provides a preparation method HDAC of the JAK and and dual-targeting inhibitor and an application of the inhibitor in the treatment of tumor diseases of mammals. The HDAC and JAK dual targeting inhibitors of the present invention may also be configured as corresponding pharmaceutical compositions or pharmaceutical preparations to improve the convenience of administration.

Diphenylamino pyrimidine compound for inhibiting kinase activity

The invention provides a diphenylamino pyrimidine compound for inhibiting the kinase activity, and particularly provides a medicinal composition of a substituted diphenylamino pyrimidine compound andapplication thereof. The compound is a compound as shown in a formula (I) in the specification, or pharmaceutically acceptable salt, prodrug, hydrate thereof or solvent compound, crystal form, N-oxideand various diastereomers thereof. The compound can be used for treating diseases which can be treated with JAK2 kinase inhibitors.